Summary by Moomoo AI
Pharma-B announced its interim financial report, showing that for the six months ended June 30, 2024, the company did not record any revenue, with a loss expanding to 130.3 million RMB, an increase of 687.0% compared to the same period last year. This loss was mainly due to an increase in research and development costs. The company's research and development expenses increased from approximately 92.3 million RMB to approximately 132.4 million RMB. The company incurred no sales costs during the reporting period due to the effective control of the COVID-19 epidemic in mainland China, leading to a contraction in market demand for lopinavir products. Other income and gains decreased from approximately 75.0 million RMB to approximately 49.0 million RMB. The comprehensive loss for the period was 121.6 million RMB. As of June 30, 2024, the company's cash and cash equivalents were approximately 2,117.2 million RMB, expected to be sufficient to support research and development activities and operations until 2028.